Diagnostic significance of urinary long non-coding PCA3 RNA in prostate cancer

Oncotarget

Volumn 8, Issue 35, 2017, Pages 58577-58586

  Wang, Tao ^a   Qu, Xiangyun ^a   Jiang, Jiajia ^b   Gao, Peng ^a   Zhao, Dingding ^a   Lian, Xueqi ^b   Li, Xiaohua ^b,c  

^a SOOCHOW UNIVERSITY   (China)

^b Aoyang Hospital Affiliated to Jiangsu University   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cell free; Diagnostic signature; Prostate cancer; Prostate cancer antigen 3; Prostate specific antigen

Indexed keywords

LONG UNTRANSLATED RNA; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; HUMAN TISSUE; MALE; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; URINE LEVEL;

EID: 85029027660     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.17272     Document Type: Article

References (29)

1. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem. 1996; 271:6379-6388.
2. Lindzey J, Kumar MV, Grossman M, Young C, Tindall DJ. Molecular mechanisms of androgen action. Vitam Horm. 1994; 49:383-432.
3. Culig Z, Santer FR. Androgen receptor signaling in prostate cancer. Cancer Metastasis Rev. 2014; 33:413-427.
4. Buzzoni C, Auvinen A, Roobol MJ, Carlsson S, Moss SM, Puliti D, de Koning HJ, Bangma CH, Denis LJ, Kwiatkowski M, Lujan M, Nelen V, Paez A, et al. Metastatic prostate cancer incidence and prostatespecific antigen testing: new insights from the European randomized study of screening for prostate cancer. Eur Urol. 2015; 68:885-890.
5. Salman JW, Schoots IG, Carlsson SV, Jenster G, Roobol MJ. Prostate specific antigen as a tumor marker in prostate cancer: biochemical and clinical aspects. Adv Exp Med Biol. 2015; 867:93-114.
6. Schalken J. Molecular diagnostics and therapy of prostate cancer: new avenues. Eur Urol. 1998; 34:3-6.
7. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999; 59:5975-5979.
8. Schmid M, Hansen J, Chun FK. Urinary prostate cancer antigen 3 as a tumour marker: biochemical and clinical aspects. Adv Exp Med Biol. 2015; 867:277-289.
9. Graham J, Baker M, Macbeth F, Titshall V, Guideline Development G. Diagnosis and treatment of prostate cancer: summary of NICE guidance. BMJ. 2008; 336:610-612.
10. Zheng K, Dou Y, He L, Li H, Zhang Z, Chen Y, Ye A, Liu W, Kong L. Improved sensitivity and specificity for prostate cancer diagnosis based on the urine PCA3/PSA ratio acquired by sequencespecific RNA capture. Oncol Rep. 2015; 34:2439-2444.
11. Vlaeminck-Guillem V, Devonec M, Champetier D, Decaussi-Petrucci M, Paparel P, Perrin P, Ruffion A. Urinary PCA3 to predict prostate cancer in a cohort of 1015 patients. Prog Urol. 2015; 25:1160-1168, e1161-1168.
12. Albitar M, Ma W, Lund L, Albitar F, Diep K, Fritsche HA, Shore N. Predicting prostate biopsy results using a panel of plasma and urine biomarkers combined in a scoring system. J Cancer. 2016; 7:297-303.
13. Coelho FF, Guimaraes FL, Cabral WL, Salles PG, Mateo EC, Nogueira e Nogueira LM, Fonseca CE, Gomes KB. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer. Genet Mol Res. 2015; 14:13519-13531.
14. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW, Schalken JA. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002; 62:2695-2698.
15. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003; 44:8-15; discussion 15-16.
16. Vaananen RM, Rissanen M, Kauko O, Junnila S, Vaisanen V, Nurmi J, Alanen K, Nurmi M, Pettersson K. Quantitative real-time RT-PCR assay for PCA3. Clin Biochem. 2008; 41:103-108.
17. De Luca S, Passera R, Cattaneo G, Manfredi M, Mele F, Fiori C, Bollito E, Cirillo S, Porpiglia F. High PCA3 scores are associated to elevated Prostate Imaging Reporting and Data System (PI-RADS) grade and biopsy Gleason Score, at MRI/US fusion software-based targeted prostate biopsy after a previous negative standard biopsy. BJU Int. 2016.
18. Cui Y, Cao W, Li Q, Shen H, Liu C, Deng J, Xu J, Shao Q. Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis. Sci Rep. 2016; 6:25776.
19. de la Taille A. Progensa PCA3 test for prostate cancer detection. Expert Rev Mol Diagn. 2007; 7:491-497.
20. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 2006; 52:1089-1095.
21. Elshafei A, Chevli KK, Moussa AS, Kara O, Chueh SC, Walter P, Hatem A, Gao T, Jones JS, Duff M. PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy. Prostate. 2015; 75:1951-1957.
22. Malik B, Feng FY. Long noncoding RNAs in prostate cancer: overview and clinical implications. Asian J Androl. 2016.
23. McKiernan J, Donovan MJ, O'Neill V, Bentink S, Noerholm M, Belzer S, Skog J, Kattan MW, Partin A, Andriole G, Brown G, Wei JT, Thompson IM Jr, Carroll P. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncol. 2016; 2:882-889.
24. Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, de Jong H, Hessels D, Smit FP, Melchers WJ, Leyten GH, de Reijke TM, Vergunst H, et al. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol. 2016; 70:740-748.
25. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists. Adv Anat Pathol. 2006; 13:57-59.
26. Li X, Kaplun A, Lonardo F, Heath E, Sarkar FH, Irish J, Sakr W, Sheng S. HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells. Mol Cancer Res. 2011; 9:733-745.
27. Wang B, Yong H, Zhu H, Ni D, Tang S, Zhang S, Wang W, Zhou Y, Zhao W, Ding G, Zhu J, Li X, Feng Z. Abnormal amphiregulin expression correlates with gastric cancer prognosis. Oncotarget. 2016; 7:76684-76692. doi: 10.18632/oncotarget.12436.
28. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP, Schalken JA. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008; 54:1081-1088.
29. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004; 350:2239-2246.